Show simple item record

Patient-reported outcomes in patients with resected, stage III BRAF V600+melanoma treated with adjuvant dabrafenib plus trametinib: COMBI-APlus study

dc.contributor.authorGrob, J. J.
dc.contributor.authorDutriaux, C.
dc.contributor.authorDel Vecchio, M.
dc.contributor.authorRyll, B.
dc.contributor.authorRobert, C.
dc.contributor.authorGogas, H. J.
dc.contributor.authorMenzies, A. M.
dc.contributor.authorGupta, Avinash
dc.contributor.authorBanerjee, H.
dc.contributor.authorLau, M. R.
dc.contributor.authorAtkinson, V. G.
dc.date.accessioned2023-01-24T10:32:23Z
dc.date.available2023-01-24T10:32:23Z
dc.date.issued2022en
dc.identifier.citationGrob JJ, Dutriaux C, Del Vecchio M, Ryll B, Robert C, Gogas HJ, et al. Patient-reported outcomes in patients with resected, stage III BRAF V600+melanoma treated with adjuvant dabrafenib plus trametinib: COMBI-APlus study. Annals of Oncology. 2022 Sep;33(7):S911-S2. PubMed PMID: WOS:000866211601074.en
dc.identifier.doi10.1016/annonc/annonc1059en
dc.identifier.urihttp://hdl.handle.net/10541/625963
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/annonc/annonc1059en
dc.titlePatient-reported outcomes in patients with resected, stage III BRAF V600+melanoma treated with adjuvant dabrafenib plus trametinib: COMBI-APlus studyen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentDepartment Of Dermatology And Skin Cancers, Timone Hospital AP-HM, Aix-Marseille University, 13385en
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record